Add BrightSurf on Google Email

Study: ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care

A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.

SourceUniversity of Miami Miller School of Medicine·JournalJCO Global Oncology·DateJan 9, 2026

Large-scale study provides real-world data on rare side effect of cancer immunotherapy

A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.

SourceMass General Brigham·JournalBlood·TypeObservational study·DateDec 12, 2025

USC researchers develop next-generation CAR T cells that show stronger, safer response in animal models

Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.

SourceKeck School of Medicine of USC·JournalScience Translational Medicine·TypeExperimental study·DateDec 10, 2025

From lab to clinic: CU Anschutz launches Phase 1 clinical trial of promising combination therapy for resistant ovarian cancer

Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.

SourceUniversity of Colorado Anschutz·JournalCancer Research Communications·DateDec 4, 2025

Why monkey studies may mislead research on cancer immunotherapy drugs targeting TIGIT

Researchers have discovered that rhesus macaques shed TIGIT from immune cell surfaces when exposed to plasmin, a natural enzyme involved in blood clot breakdown. This creates a soluble form of TIGIT that can still bind anti-TIGIT monoclonal antibodies, potentially leading to misleading safety and efficacy data for human trials.

SourceUniversity of California - Davis Health·JournalJournal of Biological Chemistry·TypeExperimental study·DateNov 24, 2025

Chinese Medical Journal Study reveals circulating tumor cells' immune evasion strategies

A recent review in the Chinese Medical Journal uncovers how circulating tumor cells evade immune elimination, highlighting their interactions with immune cells and blood components. The study suggests new therapeutic targets, including anti-platelet therapy and immune checkpoint inhibitors, to combat cancer metastasis.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateNov 6, 2025

Mass General Brigham researchers harness tumor cells to boost antitumor immunity in preclinical cancer models

Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.

SourceMass General Brigham·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 3, 2025

Decoding the T-cell burst: Signature genes that predict T-cell expansion in cancer immunotherapy

Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.

SourceTokyo University of Science·JournalNature Communications·TypeExperimental study·DateOct 21, 2025

Combination of immunotherapy and targeted therapy improves survival for patients with advanced colorectal cancer

Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.

Targeted immunotherapy combination offers hope to older adults with leukemia

Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 20, 2025

ESMO: 10-year survival data for lung cancer immunotherapy, new PSMA-targeted therapy for recurrent prostate cancer, promising results in metastatic colorectal and urothelial cancers

UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

A new class of anti-cancer agents—antibody-drug conjugates (ADCs)—has unveiled compelling evidence that can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer. The phase III DESTINY-Breast05 and DESTINY-Breast11 trials have shown superior efficacy and improved disease-free survival rates, positionin...

Repeated brain tumor sampling uncovers treatment response in patients with glioblastoma

A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.

SourceMass General Brigham·JournalScience Translational Medicine·TypeExperimental study·DateOct 8, 2025

Researchers develop new method for generating natural killer cells to fight cancer

A new method has been developed to generate induced natural killer cells and CAR-engineered NK cells from cord blood-derived hematopoietic stem and progenitor cells. This approach increases the induction efficiency of NK cells and lowers the cost of CAR engineering, offering a promising avenue for cancer immunotherapy.

SourceChinese Academy of Sciences Headquarters·JournalNature Biomedical Engineering·DateOct 7, 2025

Successful development of multifunctional liquid metal nanocomposites for cancer photoimmunotherapy

The research team developed multifunctional nanocomposites that demonstrate excellent tumor-targeting capability through the EPR effect. Irradiation with near-infrared laser light achieved multidimensional therapeutic effects, including complete elimination of transplanted mouse cancers within 5 days.

SourceJapan Advanced Institute of Science and Technology·JournalAdvanced Composites and Hybrid Materials·DateSep 25, 2025

Genetic screening technique could enhance CAR-T therapies for multiple myeloma and other cancers

Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.

SourceMass General Brigham·JournalNature·TypeExperimental study·DateSep 24, 2025

Chinese Medical Journal review highlights neoadjuvant therapy’s promise in advanced colon cancer treatment

Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateSep 19, 2025

Repurposing a diabetes medication to prime CAR T cancer targets

UCSF researchers develop a new strategy to prime CAR T cell therapy by combining it with diabetes drugs, increasing the efficacy of NECTIN4-CAR T cells in treating urothelial carcinoma. The study shows that using thiazolidinediones enhances NECTIN4 expression, making tumor cells more susceptible to the treatment.

SourceUniversity of California San Francisco Medical Center·JournalNature Communications·TypeExperimental study·DateSep 10, 2025